title: [Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report].
abstract: There is a new era of treatment options since introduction of new biological targeted therapies (tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors) in renal cell cancer. However, in patients who developed brain metastases, there is still treatment dilemma about an optimal therapeutic scenario, particularly in the subgroup of patients with-out disease progression outside the central nervous system. The objective of this case report is to present that it is possible to continue the same targeted therapy after development of brain metastasis after application of local whole brain irradiation with meaningful overall survival.
authors: Onkologická klinika LF UK a Národný onkologický ústav, Bratislava. jobert878@gmail.com
authors: J
authors: J
authors: Obertova
authors: M
authors: M
authors: Mego
authors: P
authors: P
authors: Palacka
authors: J
authors: J
authors: Rajec
authors: M
authors: M
authors: Chovanec
authors: J
authors: J
authors: Mardiak
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011758:Pyrroles; D020123:Sirolimus; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib; D020123:Sirolimus